Pharmacy Updates (@PharmacyUpdates) header
Pharmacy Updates (@PharmacyUpdates) profile picture

Pharma / Med Tech / Health innovation updates

Joined July 2009
Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)Photo by Pharmacy Updates (@PharmacyUpdates)
Lilly's oral GLP-1 orforglipron (Foundayo) met its primary endpoint in the Phase 3 ATTAIN-OSA programme. The results were presented at the AHA Scientific Sessions on 9 November and published simultaneously in JAMA. A once-daily pill reducing sleep apnoea severity suggests the benefits of this class extend well beyond weight and glycaemic control. Pharmacists counselling OSA patients on CPAP adherence may soon be discussing a pharmacologic option alongside it. #GLP1 #SleepApnea #Orforglipron #ClinicalPharmacy #PharmacyTwitter lifesciencedaily.news/?p=163…
1
1
1
453
BMS' LPA1 antagonist admilparant met its primary endpoint in an IPF study at the 60mg dose, showing a statistically significant improvement in forced vital capacity over placebo, though a miss at the higher dose leaves analysts awaiting full data. IPF has been one of the most treatment-resistant conditions in respiratory medicine. A new mechanism class getting a Phase 3 win is significant news for respiratory pharmacists and patients who have exhausted current options. #IdiopathicPulmonaryFibrosis #RespiratoryPharmacy #ClinicalTrials #BMS #PharmacyTwitter biospace.com/drug-developmen…
1
521
New Bloomberg Intelligence data shows GLP-1 pill users curbed snacking less than injection users: 74% versus 80% for salty snacks, and 76% versus 82% for baked goods. Route of administration is now a clinical decision, not just a patient preference. #GLP1 #OralGLP1 #ObesityMedicine #PharmacyTwitter bloomberg.com/news/articles/…
1
1
4
735
Yale researchers have identified an unexpected mechanism that challenges a long-held assumption about the brain’s hunger circuitry, and it may fundamentally change how we understand GLP-1s. We have been prescribing these drugs for years. We still do not fully know how they work in the brain. The pharmacology of this class keeps rewriting itself. #GLP1 #Neuropharmacology #ObesityMedicine #PharmacyTwitter news.yale.edu/2026/08/10/new…
1
1
643
Pharmacy Updates retweeted
The GLP-1 family of drugs is emerging to be potentially transformative for addiction medicine. This new @jclinicalinvest paper succinctly reviews the biology, epidemiology, randomized trials, and the gaps needed to fill in @Lorenzo__Leggio jci.org/articles/view/211153
12
95
5
333
30,678
Pharmacy Updates retweeted
Brazilian seizures of illegal GLP-1 weight-loss drugs are soaring, and health officials worry the country may be one of the most exposed to the drugs' unintended consequences, as customers are driven toward the cheaper, smuggled and unapproved injections reut.rs/4cih8vX
4
19
1
69
170,354
Pharmacy Updates retweeted
A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. Full study results: nej.md/4wW5wGB
2
43
5
156
42,345
Pharmacy Updates retweeted
While GLP-1 medicines can be incredibly effective, it's natural to have questions raised about the overall safety. Currently, the main side effects shown are primarily found with abdominal pain, vision changes, or quick mood changes. Also, these medications need to be continued long-term, and stopping often leads to weight and risk-factor regain. To learn more in-depth about the risk factors involved, tap the link: mdsc.pe/4xXwChq
7
1
19
4,519
Merck and Moderna’s personalised mRNA cancer vaccine Intismeran, combined with Keytruda, slowed melanoma recurrence and its spread to other organs in a Phase 3 trial of over 1,000 patients. This is the first randomised Phase 3 trial to definitively prove the benefit of neoantigen vaccines. #mRNA #OncologyPharmacy #CancerVaccine #Melanoma #PharmacyTwitter statnews.com/2026/08/19/mrna…
4
713
Pharmacy Updates retweeted
Engineered CAR-T cells induce long-lasting remission in rheumatoid arthritis with a single infusion worldpharmanews.com/research…
1
1
610
Eli Lilly bets $3.8B on psychedelics 🧠 Lilly just dropped $3.8 billion on a psychedelics deal — the same week an oral PCSK9 inhibitor got approved. The largest pharma company on earth is now in the psychedelic medicine space. #PsychedelicMedicine #EliLilly #ClinicalPharmacy #PharmacyTwitter lifesciencedaily.news/weekly…
509
Brand new lung cancer drug approved. The FDA approved zidesamtinib for previously treated ROS1-positive non-small cell lung cancer — a targeted therapy showing durable responses and strong activity against brain metastases. Brain mets in NSCLC have historically been a therapeutic dead end. Not anymore. Oncology pharmacists. #LungCancer #TargetedTherapy #OncologyPharmacy #FDA #PharmacyTwitter afs.lambda-bio.com/blog/top-…
500
Menopausal hormone treatment and breast cancer thelancet.com/journals/landi… #MHT #HRT #breastcancer #Womenshealth
14
25
2,830
🚨 Medicare just changed the game for GLP-1s. As of July 1, eligible Medicare Part D beneficiaries can now access Wegovy, Zepbound and Foundayo for weight loss — for a $50 monthly copay through the new GLP-1 Bridge program. This is the first time Medicare has ever covered GLP-1s prescribed solely for obesity. The program runs through December 31, 2027 — after which patients could lose access unless CMS extends it or Congress changes the law. Pharmacists — your Medicare patients are about to start asking questions. Know the eligibility criteria, the prior authorisation requirements, and that the $50 copay does NOT count toward their Part D out-of-pocket limit. Counsel accordingly. 👇 #GLP1 #Medicare #ObesityMedicine #PharmacyTwitter #ClinicalPharmacy cms.gov/medicare/coverage/pr…
2
3
602
Pharmacy Updates retweeted
Among patients with multivessel coronary artery disease who were in stable condition 1 year after stenting, an additional year of DAPT led to a lower risk of ischemic events than aspirin alone, without increased bleeding. Full DAPT-MVD trial results: nej.md/4wLDIox Editorial: Balancing the Scales — Extended DAPT in Coronary Artery Disease nej.md/4gAVqpZ
3
79
4
223
30,676
Pharmacy Updates retweeted
"The world’s largest drugmaker is betting big on preventive medicines" The future of medicine is not just to come up with more treatments, which has been the fixation for pharma companies. It can and should be to prevent diseases, with what I call "prevmeds." We're starting to see a shift. economist.com/business/2026/…
19
110
14
489
61,444